0000950170-24-013350.txt : 20240209 0000950170-24-013350.hdr.sgml : 20240209 20240209165631 ACCESSION NUMBER: 0000950170-24-013350 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240207 FILED AS OF DATE: 20240209 DATE AS OF CHANGE: 20240209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Zeng Ling CENTRAL INDEX KEY: 0001824252 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40657 FILM NUMBER: 24615850 MAIL ADDRESS: STREET 1: C/O DICERNA PHARMACEUTICALS, INC. STREET 2: 33 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Omega Therapeutics, Inc. CENTRAL INDEX KEY: 0001850838 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 140 FIRST STREET, SUITE 501 CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: (617) 949-4360 MAIL ADDRESS: STREET 1: 140 FIRST STREET, SUITE 501 CITY: CAMBRIDGE STATE: MA ZIP: 02141 4 1 ownership.xml 4 X0508 4 2024-02-07 0001850838 Omega Therapeutics, Inc. OMGA 0001824252 Zeng Ling C/O OMEGA THERAPEUTICS, INC. 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141 false true false false See Remarks false Stock Option (Right to Buy) 3.59 2024-02-07 4 A false 125000 0.00 A 2034-02-06 Common Stock 125000 125000 D The option vests and becomes exercisable with respect to 25% of the underlying shares on February 7, 2025 and in twelve (12) equal quarterly installments thereafter such that the option will become fully vested and exercisable on February 7, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Chief Legal and Administrative Officer /s/ Barbara Chan as Attorney-in-Fact for Ling Zeng 2024-02-09